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ABSTRACT
Introduction: The aim of the present study was
to compare the confocal and clinical features of
newly diagnosed glaucoma patients receiving
unpreserved prostaglandins (tafluprost) versus
preserved prostaglandins (latanoprost).
Materials and Methods: 40 patients were
randomized to tafluprost 0.0015% (20
patients; 32 eyes) or latanoprost
0.005% ? benzalkonium chloride 0.02% (20
patients; 35 eyes) once daily for 1 year.
Inclusion criteria were new glaucoma
diagnosis, and no ocular treatments for
6 months before the study. Patients were
evaluated at baseline and every 3 months with
a complete ophthalmologic evaluation,
Schirmer’s test, break-up time test, confocal
microscopy of the central cornea, and
measurement of intraocular pressure (IOP).
Investigators were masked to treatment. Both
eyes were analyzed if they fulfilled inclusion
criteria. Treatments and changes between
follow-up and baseline were compared by
analysis of variance (ANOVA), t test and Chi-
square test.
Results: At baseline, the two groups had similar
age, ocular surface and confocal findings;
keratocyte activation was present in 40%,
branching pattern in 85%, and beading in
75%, with no inter-group differences. At
follow-up, no significant clinical changes were
detected, apart from a drop of IOP by
3.6–4.2 mmHg in the two groups (p\0.001,
with no difference between treatments). Despite
inter-treatment ANOVA for confocal
microscopy being negative, subtle changes
were present. During follow-up, all eyes
without nerve branching pattern at baseline
progressively developed it when treated with
latanoprost, whereas no change occurred using
tafluprost treatment (p = 0.05). None of the eyes
without beading at baseline developed it at the
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end of the study in the tafluprost group,
whereas beading did occur in 75% of patients
treated with latanoprost (p = 0.05). Both
treatments were associated with increased
keratocyte activation at follow-up; the change
from baseline was statistically significant after
month 3 with latanoprost (p = 0.02) and after
month 6 with tafluprost (p = 0.04).
Conclusions: The two study treatments had
similar clinical effects, but tafluprost had a
more favorable profile for some confocal
parameters of the cornea.
Funding: Merck Sharp & Dohme International.
Keywords: Confocal microscopy; Cornea;
Glaucoma; Intraocular pressure (IOP);
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INTRODUCTION
The beneficial effect of intraocular pressure
(IOP) lowering treatments to reduce glaucoma
progression has been demonstrated by a
number of multicenter, randomized studies
[1–4]. On the other hand, more recent studies
have also shown the detrimental effects of
medical treatments for glaucoma on the ocular
surface [5–11]. It has been shown that
prostaglandin analogs have inflammatory
effects [5–9, 11], yet the vast majority of side
effects are due to preservatives, in particular
benzalkonium chloride (BAK), which is the most
toxic and most used of ophthalmic preservatives
[5–11]. BAK effects are dose dependent [7–12],
and this is relevant considering that most
glaucoma patients receive more than one IOP-
lowering treatment [4]. Chronic BAK exposure is
also associated with reduced efficacy of
glaucoma surgery [13]. As a consequence,
preservative-free treatments are preferable for
glaucoma, as for all chronic eye diseases [14].
Confocal microscopy is a recent technique
which enables ophthalmologists to detect
subtle inflammatory and toxic changes of the
ocular surface [15]. By means of confocal
microscopy, BAK has been shown to reduce
the density of conjunctival goblet cells [16, 17],
of conjunctival and corneal epithelial cells [17],
and to deteriorate the normal characteristics of
corneal nerves [18–20].
Still, timing of occurrence of ocular surface
changes when starting IOP-lowering treatments
is an unexplored issue. Tafluprost is the most
recent unpreserved prostaglandin analog
introduced in clinical practice and it is
characterized by the absence of BAK.
To the best of the author’s knowledge, this is
the first study to investigate and compare, from
both clinical and confocal viewpoints, the
effects of preserved and unpreserved
prostaglandin analogs in newly diagnosed
glaucoma patients with normal ocular surface.
MATERIALS AND METHODS
A randomized, masked, prospective study was
carried out to test the primary hypothesis that
treatment with preserved prostaglandins
induces confocal changes of the cornea (both
stromal inflammation and toxic damage to the
sub-basal nerves) and that these anatomical
changes would induce clinical changes, as
detected during a general ophthalmic
examination.
Inclusion Criteria
Inclusion criteria for the present study were:
diagnosis of ocular hypertension (OH), primary
open-angle glaucoma (POAG),
pseudoexfoliative glaucoma or normal tension
glaucoma, according to the definitions of the
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European Glaucoma Society Guidelines [21]; no
previous treatments to reduce IOP and no
treatment with any BAK-preserved eye drop for
at least 6 months before the study; no
fluorescein staining at baseline and no
observable signs of ocular surface disease.
Exclusion Criteria
Exclusion criteria for the present study were:
unwillingness to sign informed consent;
aged\18 years; any ocular condition that was
of safety concern or interfering with the study
results; any ocular condition requiring the use
of eye drops during follow-up (i.e., dry eye);
closed/barely open anterior chamber angles or
history of acute angle closure; ocular surgery or
argon laser trabeculoplasty within the last year;
ocular inflammation/infection occurring
within 3 months prior to pre-trial visit;
presence of the following ocular conditions:
dry eye, moderate–severe blepharitis, Rosacea,
Sjogren syndrome, pterygium or use of contact
lens(es); hypersensitivity to BAK or to any
other component of the trial drug solutions;
any corneal pathology; diabetes at any stage;
other abnormal condition or symptom
preventing the patient from entering the trial
(need for more than 1 IOP-lowering
treatment), according to the investigator’s
judgment; refractive surgery patients; women
who were pregnant, of childbearing potential
and not using adequate contraception or
nursing; inability to adhere to treatment/visit
plan.
Clinical Plan
The study protocol comprised 5 visits
(performed at Eye Clinic of San Paolo Hospital,
Milan, Italy): Baseline, Month 3, Month 6,
Month 9 and Month 12.
At baseline, a clinical evaluator performed a
complete ophthalmologic evaluation to
confirm diagnosis. The following examinations
were done in the following sequence: anterior
segment examination, Schirmer’s test and
break-up time test. Thereafter, a confocal
evaluator performed confocal microscopy of
the central cornea. Finally, contact
measurements were carried out in the
following order: IOP, pachymetry and
gonioscopy. A 15-min interval between two
consecutive tests was observed.
A study coordinator recorded medical
history and then randomized patients into two
groups: one group to receive unpreserved
(tafluprost 0.0015%, Saflutan, Santen
Pharmaceutical, Osaka, Japan) and one group
to receive preserved prostaglandins (latanoprost
0.005% ? BAK 0.02%, Xalatan, Pfizer S.r.L.,
Latina, Italy) once daily to both eyes
(randomization of 1:1, by means of a list of
random numbers). Being patients treated to
both eyes, a control group was not available.
During the study, patients were instructed not
to use any other topical treatment other than
the study medication. The confocal and the
clinical investigators were masked to treatment.
Confocal and clinical examinations, as
described above, were repeated at months 3, 6,
9 and 12.
Adherence to treatment, medical history,
and side effects were checked by study
coordinator at follow-up visits. Adverse effects
were recorded. Symptoms were evaluated by
means of comparison of ophthalmic
medications for tolerability (COMTOL)
questionnaire [22].
Corneal Confocal Biomicroscopy
The second version of Heidelberg Retina
Tomograph (Heidelberg Engineering,
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Heidelberg, Germany) is endowed with a lens
system called the [Rostock Cornea Module
(RCM)], and allows an in vivo confocal study
of the ocular surface. The laser source used in
the RCM is a diode laser with a wavelength of
670 nm. The acquired two-dimensional images
have a definition of 384 9 384 pixels over an
area of 400 lm 9 400 lm with lateral digital
resolution of 1 lm/pixel and a depth resolution
of 2 lm/pixel.
After administration of one drop of 0.4%
oxybuprocaine and one drop of a lubricant gel
(0.2% carbomer), the patient was asked to fixate
on a small, bright, red light as the examination
was performed in the contralateral eye. Correct
alignment and contact with the cornea were
monitored using the images captured by a
camera tangential to the eye. The distance
from the cornea to the microscope was kept
stable using a single-use contact element in
sterile packaging, (TomoCap, Heidelberg
Engineering, Heidelberg, Germany). The
examination took about 7 min per eye; 5
images of each cornea layer and of the sub-
basal layer were collected, both in central area.
The highest resolution images taken of the
different layers were considered for the analysis.
Test–retest variability of confocal microscopy
of the central cornea was tested at the
beginning of the study using the following
method. 5 eyes of 5 volunteers were tested 3
times each: twice during the same day (at 9 a.m.
and at 11 a.m.) and once the day after (at
9 a.m.). The confocal operator evaluated these
images and found an agreement of 80% or more
for all parameters.
Sample Size Calculation
Given the paucity of information available on
the effects of treatments with BAK-free
prostaglandin on the ocular surface studied
by confocal imaging, sample size calculation
for this pilot study may be imprecise. The
outcome of the study was corneal
inflammation at confocal microscopy (defined
as activation of anterior stroma, changes of
nerve morphology, increase of dendritic cells).
If a worth-detecting difference of 40% between
the two groups is assumed, the presence of
subclinical inflammation in 30% of normal
cases, a one-tailed distribution in favor of the
BAK-free arm of the study, a = 0.05, b = 0.2, a
sample of 20 eyes would be necessary [20, 23,
24]. It was decided to overpower the study
including all treated eyes (a control group was
absent in any case, being patients treated to
both eyes), and this gave a study power of
nearly 90%.
Statistical Analysis
All available data were analyzed (i.e., all eyes
receiving study product were analyzed). The
dataset was analyzed by means of linear and
generalized, mixed-effect models of analysis of
variance (ANOVA), with a post hoc test. In case
of multiple comparisons, t test and Chi-square
tests with Bonferroni–Holm correction were
used. R open-access software was used (version
3.1.3, R foundation for statistical computing,
Vienna, Austria).
Compliance with Ethics
This present study was performed at the Eye
Clinic, Department of Medicine, Surgery and
Odontoiatry, San Paolo Hospital, University of
Milan, Italy.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(University of Milan, Italy) and with the
Helsinki Declaration of 1964, as revised in
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2013. Informed consent was obtained from all
patients for being included in the study.
RESULTS
Forty consecutive patients with new diagnosis
of glaucoma or ocular hypertension were
enrolled between January and July 2013. The
study included 32 and 35 eyes in the tafluprost
and latanoprost groups, respectively.
Demographic characteristics of the study
population and main study results are given in
Tables 1, 2 and 3. The two groups had similar
age and ocular surface and confocal findings at
baseline (Figs. 1, 2). At the beginning of the
study, activation of anterior stromal keratocytes
was present in 40% of total patients (28% and
50% of subjects in latanoprost and tafluprost
groups, respectively, p = 0.08); branching
pattern was present in about 85% of patients,
and beading in 75% of cases.
During a 1-year interval from treatment
beginning, no significant clinical changes were
detected, apart from a drop of IOP of
3.6–4.2 mmHg in the two groups (p\0.001,
with no statistically significant difference
between treatments; ANOVA).
Confocal microscopy was similar between
groups and between time points when analyzed
by ANOVA. Yet, subtle changes occurring on
the morphology of the cornea were shown at
follow-up. All patients without branching
pattern of sub-basal nerves at baseline
progressively (from 9 to 12 months) developed
this pattern when treated with latanoprost,
whereas no change occurred at follow-up in
subjects treated with tafluprost (p = 0.04,
month 12). None of the patients without
beading at baseline developed beading at the
end of the study in tafluprost group, whereas
this occurred in 6/8 (75%) patients treated with
latanoprost (p = 0.05).
Both treatments were associated with an
increase of activation of anterior stromal
keratocytes at follow-up; the change from
baseline was statistically significant 3 months
after starting treatment with latanoprost
(p = 0.02) and 6 months after tafluprost
(p = 0.04).
A small and not significant increase of
dendritic cells density occurred over time,
with no difference between treatments.
No significant side effects were detected with
any treatment during the study. No significant
changes of symptoms were found, as evaluated
by COMTOL scale, at follow-up in the two
groups. Adherence to treatment was high
(96%), and no study discontinuation occurred.
DISCUSSION
This paper explored the effects of tafluprost and
latanoprost on a population of newly diagnosed
POAG and OH with normal ocular surface, and
the two treatments were found to have the same
IOP-lowering effect and clinical tolerability over









Age years (SD) 68.5 ± 12.3 63.4 ± 14.4 65.9 ± 13.5
Sex f/m 7/10 8/10 15/20
Refraction 0.98 ± 0.28 1.1 ± 0.28 1.03 ± 0.28
IOP mmHg
(SD)
18.5 ± 4.0 18.5 ± 5.5 18.5 ± 5.0
IOP intraocular pressure, f/m female/male, SD standard
deviation
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1 year of follow-up, thus confirming previous
findings [25–27].
One novelty of the present study is that by
means of a parallel randomization, prospective
and masked design, the two treatments were
also compared using confocal microscopy.
Using this method, it was shown that a
subgroup of otherwise normal subjects at
baseline have subclinical corneal patterns
(activation of anterior stromal keratocytes,
nerve beading and branching). The number of
cases with activation of keratocytes increased
over time, thus confirming previous findings on
the pro-inflammatory effect of prostaglandin
analogs (regardless of BAK) [23]. Of the changes
occurring during follow-up on sub-basal nerves,
beading and branching were significantly lower
in patients receiving tafluprost. Another paper
recently compared the corneal confocal
findings of the two treatments using a non-
randomized design, and showed that tafluprost
has a favorable safety profile [24].
The main difference between the two study
treatments is the absence of BAK in tafluprost
formulation. BAK has been used for decades on
nearly all ophthalmic formulations with an
overall low percentage of serious side effects
[28], even if recent studies demonstrated that
BAK frequently causes relevant changes on the
ocular surface, particularly when inspected by
confocal microscopy [28].
Little is known on the timing of occurrence
of ocular surface changes when starting IOP-
lowering treatments; in the present study it was
shown that keratocyte activation (which was
present at baseline in about one-third of eyes)
increases immediately after the treatment is
started and it tends to increase over time,
whereas morphological changes of the nerves
are present only after 9–12 months.
Most of the corneal changes found in
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have been attributed to BAK. In particular, BAK
has a dose-dependent apoptotic action [29]
which has been shown to disrupt the
epithelial barrier of both conjunctiva [16, 30]
and cornea [11]; at ultrastructural levels, BAK
induces a massive reduction of goblet cells [16,
30] and an anatomical disruption of corneal
glycocalyx and microvilli [11]. In the most
severe cases, deeper layers of the ocular surface
can also be involved by BAK exposure:
conjunctival fibrosis and keratinization have
been reported [31]. Most recently, BAK exposure
Fig. 1 Confocal images of a patient treated with taﬂuprost.
a Sub-basal plexus at baseline. b Sub-basal plexus at month
12: no relevant changes of density, length, morphology are
shown. c Anterior stroma at baseline; no keratocyte
activation is present. d Anterior stroma at month 12: no
changes are shown; keratocyte activation is absent
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has been associated also with anterior chamber
inflammation [32].
From the literature, the use of BAK-free
treatments is preferable in all cases [16, 18, 30,
33, 34]. Studies comparing BAK and BAK-free
treatments for glaucoma showed the superiority
of BAK-free treatments on clinical findings [33,
34] and, by means of confocal microscopy,
conjunctival [16, 30] and corneal [18] findings.
The non-randomized, cross-sectional paper by
Fig. 2 Confocal images of a patient treated with
latanoprost. a Sub-basal plexus at baseline. b Anterior
stroma at baseline; no keratocyte activation is present.
c Sub-basal plexus at month 12: disruption of normal nerve
structure is shown: branching and beading are present, and
nerve is tortuous; density is overall conserved. d Anterior
stroma at month 12 showing keratocyte activation
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Martone et al. [18] was one of the first to suggest
that patients receiving unpreserved treatments
for glaucoma have confocal findings more
similar to controls than to patients treated
with BAK-preserved eye drops.
Regardless of the exposure to BAK, it has
been suggested that stromal activation may be
facilitated by the pro-inflammatory activity of
prostaglandin analogs [23]. Even if other studies
found that activation may be similar for beta-
blockers and prostaglandins [18, 20], the data
seem to support the effect of the drug itself on
the keratocyte activity.
The beneficial effect of switching from
preserved to unpreserved prostaglandin
treatment has been explored by a recent study
which showed, over a 1-year period, an increase
in epithelial and nerve densities, a reduction of
keratocyte activation, a reduction of bead-like
formations and nerve tortuosity [25]. Despite
these premises, the present study seems to
indicate that such findings may not be
clinically relevant for newly diagnosed
glaucoma patients, without ocular surface
disease, receiving low doses of BAK (i.e.,
monotherapy) for a short period of time.
Clinical data and symptoms, in fact,
overlapped in the two study groups at all
visits. The confocal difference of the two
treatments may gain relevance in patients
with longer follow-up, with concomitant
ocular surface disease, or exposure to higher
BAK concentrations due to concomitant use of
preserved eye drops. These factors were outside
the scope of the study, but these patients will
have continued follow-ups to detect possible
future clinical and confocal changes.
Readers should be aware that this study
reflects the limits of confocal microscopy, i.e.,
subjectivity and limited repeatability. The area
investigated by this device is also very small and
may be not representative of the whole cornea.
The data are comparable to those available in
literature for corneal confocal microscopy of
normal patients, with the exception of dendritic
cells, which were lower in the present study
sample than in literature (although Zhivov et al.
[35]. suggested that dendritic cell density in
normal subjects may range from 0 to 64/mm2).
In general, data on confocal microscopy have a
large span of normality, as shown in Table 4
[35–45]. Moreover, the discrimination between
normal and abnormal findings at confocal
investigation is not always univocal; for
example, the role played by branching,
tortuosity or abnormally high or abnormally
low reflectivity is debated [16, 18–20].
Due to the paucity of data on confocal
microscopy in newly treated glaucoma
patients, sample size assumptions were
approximate; the inclusion of all available eyes
in analysis increased the statistical power of the
study but could also limit its validity.
Nevertheless, this paper has the merit of a
randomized, double-blinded design; the
confocal evaluators were blinded to the
characteristics of the patients and evaluated
images in a blinded fashion.
CONCLUSION
In conclusion, the present study found out that
the low daily exposure to BAK of patients
treated with latanoprost may facilitate the
development of confocal changes of the
cornea, which occurred less frequently on
patients treated with tafluprost. Activation of
anterior stromal keratocytes was present at
baseline in one-third of cases and increased at
follow-up, probably due to the pro-
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inflammatory activity of prostaglandin analogs.
From a clinical viewpoint, the two treatments
had similar IOP-lowering effect and tolerability.
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